IP
TEVA icon

Intellectus Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Intellectus Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$19K – 633
2017
Q4 		$19K Hold
1,000
– – 0.01% 434
2017
Q3 		$18K Hold
1,000
– – 0.01% 556
2017
Q2 		$33K Hold
1,000
– – 0.01% 437
2017
Q1 		$32K Hold
1,000
– – 0.02% 398
2016
Q4 		$36K Buy
+1,000
New +$39.9K 0.02% 377

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Intellectus Partners's TEVA Position: Q1 2018 in Review

Intellectus Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 1,000 shares — an estimated $19K sold.

Intellectus Partners first reported a position in TEVA in Q4 2016 and held it in 5 quarters. The position peaked at $36K in Q4 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Intellectus Partners reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Intellectus Partners sold 1,000 Teva Pharmaceuticals shares in Q1 2018, an estimated $19K.
  • Intellectus Partners first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Intellectus Partners's Teva Pharmaceuticals position peaked at $36K in Q4 2016.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Intellectus Partners's 13F filing for Q1 2018, filed 15 May 2018.